Overview

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Status:
Not yet recruiting

Trial end date:
2020-10-15

Target enrollment:

Participant gender:

Summary

This is a Phase 1, randomized, open-label, 2-way crossover, pharmacokinetic study in adult patients with hematological malignancies eligible to receive either cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen or rituximab-CHOP (R-CHOP) regimen.

Phase:

Phase 1

Details

Lead Sponsor:

Acrotech Biopharma LLC

Collaborator:

Axis Clinicals Limited

Treatments:

Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Prednisone
Vincristine